Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALXO

ALXO - ALX Oncology Holdings Inc. Stock Price, Fair Value and News

14.70USD+0.19 (+1.31%)Market Closed
Watchlist

Market Summary

USD14.70+0.19
Market Closed
1.31%

ALXO Stock Price

View Fullscreen

ALXO RSI Chart

ALXO Valuation

Market Cap

732.3M

Price/Earnings (Trailing)

-5.01

Price/Sales (Trailing)

598.08

EV/EBITDA

-5.74

Price/Free Cashflow

-6.49

ALXO Price/Sales (Trailing)

ALXO Profitability

EBT Margin

-10441.46%

Return on Equity

-86.54%

Return on Assets

-66.35%

Free Cashflow Yield

-15.41%

ALXO Fundamentals

ALXO Revenue

Revenue (TTM)

1.2M

ALXO Earnings

Earnings (TTM)

-146.0M

Earnings Growth (Yr)

-44.37%

Earnings Growth (Qtr)

-49.27%

Breaking Down ALXO Revenue

Last 7 days

12.7%

Last 30 days

10.5%

Last 90 days

66.8%

Trailing 12 Months

94%

How does ALXO drawdown profile look like?

ALXO Financial Health

Current Ratio

5.66

Debt/Equity

0.06

Debt/Cashflow

-11.63

ALXO Investor Care

Shares Dilution (1Y)

22.24%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20204.4M3.7M2.4M1.2M
20192.7M3.4M4.1M4.8M
20180002.1M

Tracking the Latest Insider Buys and Sells of ALX Oncology Holdings Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 14, 2024
pinto shelly
acquired
-
-
15,000
svp, finance and cao
Feb 14, 2024
randolph sophia
acquired
-
-
30,000
chief medical officer
Feb 14, 2024
pons jaume
acquired
-
-
30,000
president & cso
Feb 14, 2024
garcia peter s
acquired
-
-
25,000
chief financial officer
Feb 14, 2024
lettmann jason
acquired
-
-
60,000
chief executive officer
Jan 04, 2024
pinto shelly
sold
-36,956
13.602
-2,717
svp, finance and cao
Dec 29, 2023
pinto shelly
sold
-24,530
15.04
-1,631
svp, finance and cao
Dec 29, 2023
randolph sophia
sold
-47,045
15.04
-3,128
chief medical officer
Dec 29, 2023
garcia peter s
sold
-28,470
15.04
-1,893
chief financial officer
Dec 29, 2023
pons jaume
sold
-107,972
15.04
-7,179
president & cso

1–10 of 50

Which funds bought or sold ALXO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
24.08
147,666
199,496
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
new
-
8,090,000
8,090,000
-%
Feb 15, 2024
Legal & General Group Plc
added
42.62
26,379
34,083
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
60.00
60.00
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
649,174
649,174
-%
Feb 15, 2024
Virtus ETF Advisers LLC
reduced
-34.57
53,023
104,513
0.07%
Feb 15, 2024
BARCLAYS PLC
added
65.54
535,000
664,000
-%
Feb 14, 2024
Voya Investment Management LLC
new
-
159,442
159,442
-%
Feb 14, 2024
Royal Bank of Canada
added
129
109,000
126,000
-%
Feb 14, 2024
VANGUARD GROUP INC
added
49.01
17,531,300
22,370,900
-%

1–10 of 43

Are Funds Buying or Selling ALXO?

Are funds buying ALXO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALXO
No. of Funds

Unveiling ALX Oncology Holdings Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
orbimed advisors llc
4.5%
2,255,000
SC 13G/A
Feb 14, 2024
redmile group, llc
9.6%
4,909,264
SC 13G/A
Feb 14, 2024
lsv associates, llc
2.7%
1,366,530
SC 13D/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Dec 20, 2023
lsv associates, llc
3.9%
1,950,004
SC 13D/A
Oct 16, 2023
redmile group, llc
9.6%
4,991,545
SC 13G
Oct 13, 2023
cormorant asset management, lp
5.28%
2,630,000
SC 13G
Feb 14, 2023
orbimed advisors llc
5.6%
2,266,000
SC 13G
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Jun 10, 2022
wellington management group llp
2.77%
1,128,101
SC 13G/A

Recent SEC filings of ALX Oncology Holdings Inc.

View All Filings
Date Filed Form Type Document
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13D/A
13D - Major Acquisition
Feb 09, 2024
SC 13G/A
Major Ownership Report
Jan 05, 2024
4
Insider Trading

Peers (Alternatives to ALX Oncology Holdings Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
35.3B
6.8B
-16.59% -47.80%
-7.48
5.15
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.0B
1.8B
-23.99% -31.71%
-43.22
10.41
76.23% 61.08%
16.3B
2.4B
-4.89% -18.90%
97.14
6.73
15.42% 18.43%
13.1B
3.7B
-7.62% -26.87%
21.93
3.55
8.87% 75.42%
MID-CAP
7.5B
396.6M
-2.06% 34.31%
-14.13
18.83
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.64
60.35
54.84% -25.61%
4.0B
240.7M
-19.08% -10.99%
-13.4
16.52
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.11
14.24
440.80% -27.84%
3.8B
726.4M
-12.60% 32.37%
-62.46
5.27
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
-3.38% -9.50%
26.46
4.74
85.90% -14.05%
687.2M
983.7M
-9.17% -57.89%
-1.26
0.7
-50.36% 17.16%
201.6M
4.9M
-14.18% -58.18%
-1.22
41.23
-57.57% 50.48%
135.5M
881.7K
289.54% 381.25%
-2.86
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

ALX Oncology Holdings Inc. News

Latest updates
InvestorsObserver15 hours ago
Simply Wall St07 Jan 202408:00 am
The Motley Fool5 months ago

ALX Oncology Holdings Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue---527,000655,0001,213,0001,256,0001,295,000--
Operating Expenses81.7%17,825,0009,809,00011,314,0005,897,0008,946,0004,290,0005,484,0005,259,000-
  S&GA Expenses26.8%5,683,0004,481,0003,172,0001,473,0001,108,000938,000679,000--
  R&D Expenses127.9%12,142,0005,328,0007,663,0003,828,0006,735,0002,210,0003,628,000--
EBITDA Margin-Infinity%-37.96--------
Interest Expenses23.4%132,000107,000107,00081,000-----
Income Taxes420.0%182,00035,00020,0004,0009,0008,0008,000--
Earnings Before Taxes-83.2%-18,592,000-10,146,000-11,311,000-5,450,000-7,755,000-3,036,000-4,189,000--
EBT Margin-Infinity%-38.49--------
Net Income-84.4%-18,774,000-10,181,000-11,331,000-5,454,000-8,835,000-4,115,000-5,178,000-5,143,000-
Net Income Margin-Infinity%-38.70--------
Free Cashflow-Infinity%-13,626,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-10.5%22024627830631834636438040042143343626210357.0011.0011.0011.0011.0011.00
  Current Assets-9.3%199220233271291317322367389412432436262101-10.00---10.00
    Cash Equivalents-48.5%20.0038.0063.0049.0049.0066.0015936438541043043425998.001059.006.009.00-8.00
  Net PPE-5.5%4.004.004.004.002.002.001.001.001.000.000.000.000.000.00-1.00---1.00
Liabilities54.5%51.0033.0038.0043.0031.0030.0020.0017.0015.0016.0014.006.0010.0012.0012.0011.009.006.004.002.00
  Current Liabilities100.0%35.0018.0022.0028.0025.0024.0015.0015.0012.0014.0014.006.007.008.00-5.00---2.00
  Long Term Debt0.7%10.0010.009.009.00--------3.004.00-5.00----
    LT Debt, Non Current0.7%10.0010.009.009.00--------3.004.00-5.00----
Shareholder's Equity-20.7%1692132402632873163443633854054184302525.002.002.002.002.002.002.00
  Retained Earnings-13.1%-440-389-355-325-294-259-226-201-173-148-132-118-99.75-89.57--72.78----53.54
  Additional Paid-In Capital1.2%6106035965905835775715655595545515483525.00-2.00---2.00
Shares Outstanding0.4%41.0041.0041.0041.0041.0041.0041.0041.0040.0040.0040.0018.00--------
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations1.7%-31,159-31,711-27,816-20,668-30,883-16,998-20,674-17,488-24,856-20,622-5,135-13,615-9,548-6,163-8,963-2,874-3,186---
  Share Based Compensation11.7%6,9646,2376,3516,2956,2075,8365,5015,6864,1912,2371,8001,7436892,85315175.0086.00---
Cashflow From Investing106.3%12,8156,21342,29510,94213,695-76,132-183,921-4,518-398--7.00-11.00631--10.0062.00----
Cashflow From Financing-132.4%-111343-1079,494-13642280.00524439731778188,361170,298-769104,9915,927----

ALXO Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 45,766$ 29,382$ 100,011$ 73,203
General and administrative7,5097,29922,24422,014
Total operating expenses53,27536,681122,25595,217
Loss from operations(53,275)(36,681)(122,255)(95,217)
Interest income2,6771,3707,6542,471
Interest expense(391)(2)(1,150)(7)
Other income (expense), net(1)(7)418(20)
Net loss$ (50,990)$ (35,320)$ (115,333)$ (92,773)
Net loss per share, basic$ (1.24)$ (0.87)$ (2.82)$ (2.28)
Net loss per share, diluted$ (1.24)$ (0.87)$ (2.82)$ (2.28)
Weighted-average shares of common stock used to compute net loss per share, basic41,147,93840,747,02640,963,01540,684,172
Weighted-average shares of common stock used to compute net loss per share, diluted41,147,93840,747,02640,963,01540,684,172

ALXO Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 19,584$ 48,822
Short-term investments170,425217,385
Prepaid expenses and other current assets9,0624,762
Total current assets199,071270,969
Property and equipment, net3,6173,889
Long-term investments6,43516,699
Other assets10,98414,932
Total assets220,107306,489
Current liabilities:  
Accounts payable13,0018,073
Payable and accrued liabilities due to related party$ 265$ 1,650
Other Liability, Current, Related Party, Type [Extensible Enumeration]us-gaap:RelatedPartyMemberus-gaap:RelatedPartyMember
Accrued expenses and other current liabilities$ 21,876$ 18,602
Total current liabilities35,14228,325
Term loan, non-current9,5759,389
Other non-current liabilities6,6385,311
Total liabilities51,35543,025
Commitments and contingencies (Note 11)
Stockholders’ equity  
Common stock, $0.001 par value; 1,000,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 41,151,819 and 40,861,386 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively4141
Additional paid-in capital609,737589,735
Accumulated other comprehensive loss(226)(845)
Accumulated deficit(440,800)(325,467)
Total stockholders’ equity168,752263,464
Total liabilities and stockholders’ equity$ 220,107$ 306,489
ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEwww.alxoncology.com
 EMPLOYEES72

ALX Oncology Holdings Inc. Frequently Asked Questions


What is the ticker symbol for ALX Oncology Holdings Inc.? What does ALXO stand for in stocks?

ALXO is the stock ticker symbol of ALX Oncology Holdings Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ALX Oncology Holdings Inc. (ALXO)?

As of Thu Feb 29 2024, market cap of ALX Oncology Holdings Inc. is 732.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALXO stock?

You can check ALXO's fair value in chart for subscribers.

What is the fair value of ALXO stock?

You can check ALXO's fair value in chart for subscribers. The fair value of ALX Oncology Holdings Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ALX Oncology Holdings Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALXO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ALX Oncology Holdings Inc. a good stock to buy?

The fair value guage provides a quick view whether ALXO is over valued or under valued. Whether ALX Oncology Holdings Inc. is cheap or expensive depends on the assumptions which impact ALX Oncology Holdings Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALXO.

What is ALX Oncology Holdings Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, ALXO's PE ratio (Price to Earnings) is -5.01 and Price to Sales (PS) ratio is 598.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALXO PE ratio will change depending on the future growth rate expectations of investors.